Analysts at Cantor Fitzgerald started coverage on shares of Align Tech (NASDAQ: ALGN) in a research report issued to clients and investors on Monday. The firm set a “buy” rating and a $37.00 price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at Zacks upgraded shares of Align Tech from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, May 1st. They now have a $38.00 price target on the stock. Separately, analysts at Barrington Research raised their price target on shares of Align Tech from $28.00 to $38.00 in a research note to investors on Wednesday, April 25th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Align Tech in a research note to investors on Tuesday, April 24th.
Align Tech traded up 1.51% on Monday, hitting $31.68. Align Tech has a 1-year low of $14.25 and a 1-year high of $34.29. The company has a market cap of $2.546 billion and a price-to-earnings ratio of 35.07.
Align Tech last released its earnings data on Monday, April 23rd. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.06. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. Analysts expect that Align Tech will post $0.29 EPS next quarter.
Align Technology, Inc. designs, manufactures, and markets the Invisalign system, a method for treating malocclusion, or the misalignment of teeth.